Abemaciclib has also been approved as a monotherapy for patients with HR-positive/HER2-negative metastatic BC who have previously received endocrine therapy and chemotherapy, based on results from single-arm phase II MONARCH-1 trial [68]. Here, ERBB2 is linked to breast cancer.